GlassScriptPhysician profile
Douglas K Basso
NPI 1295191112
$2,139.12
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $401 · 2021: $591 · 2022: $469 · 2023: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $312.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $311.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $508.56 | 2019-2022 | |
| Stryker Corporation | $502.37 | 2019-2023 | Hoffmann |
| Organogenesis INC. | $225.52 | 2019-2022 | |
| Kerecis Limited | $197.57 | 2021-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Abbott Laboratories | $181.15 | 2020 | |
| Aroa Biosurgery Incorporated | $139.66 | 2019-2020 | |
| Elite Orthopedics, LLC | $121.04 | 2021 | |
| Paragon 28, INC. | $99.68 | 2023 | Portfolio |
| Biocomposites INC | $69.18 | 2019-2020 | |
| Veryan Medical Incorporated | $37.48 | 2021 | |
| Smith+Nephew, INC. | $16.51 | 2023 | Grafix Pl, Stravix Pl |
| Abbvie INC. | $14.49 | 2021 | |
| Celularity INC. | $13.00 | 2019 | |
| Wright Medical Technology, INC. | $12.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Basso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.